YahooSeptember 22, 2026 at 2:04 PM NYLast Month
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’
In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
